Deal-hungry generic drugmaker Teva Pharmaceutical rolled out a $6.75 billion public offering on Monday as the Israel-based pharmaceutical giant looks to back its acquisitions of Allergan’s generics unit and Mexico-based drug manufacturer Rimsa, according to a statement.
Allergan and New York state have settled an antitrust suit that accused the drugmaker of steering patients away from one of its dementia drugs and toward another to avoid competition with generic versions that were coming to market.
The Federal Trade Commission has accused an apparel company endorsed by talk show host Montel Williams in New York federal court of deceiving consumers into thinking the company's copper-infused compression clothing can alleviate pain.
Sheppard Mullin Richter & Hampton LLP said it has shored up its corporate practice group in Los Angeles by tapping a former Snell & Wilmer LLP partner with experience advising on mergers and acquisitions in industries including technology, health care, oil and gas, real estate, biotechnology, entertainment and retail.
Actavis PLC asked a California judge Wednesday to rule that Travelers Property Casualty Co. of America must defend it against allegations from the city of Chicago and two California counties that misleading marketing for painkillers has fueled a wave of crime, addiction and expensive health costs.
Drugmaker Teva Pharmaceutical, led by Kirkland & Ellis LLP, unveiled a partnership on Monday with Japanese drug developer Takeda Pharmaceutical, setting up the Israel-based pharmaceutical giant for deeper access to the country’s fast-growing generics market, according to a statement.
The Supreme Court on Monday turned away Biolitec AG’s challenge to a $70 million contempt penalty and an arrest warrant for its CEO for going through with a merger expressly forbidden by a lower court’s order.
The IRS slammed Mylan Pharmaceuticals’ contention that its $400 million patent deal with Forest Laboratories was a sale rather than a license for tax purposes, telling the U.S. Tax Court that Mylan retained a host of rights and therefore has no basis to challenge a $100 million tax bill.
The U.S. Supreme Court on Monday rejected medical supplier Covidien PLC’s efforts to recoup more than $176 million it had been awarded in a patent dispute with a unit of Johnson & Johnson, despite protests that a “secret" prototype shouldn't be considered as prior art.
Eldora Ellison's time in the laboratory has helped her score victories for biotechs and their cutting-edge treatments, making the Sterne Kessler Goldstein & Fox PLLC director a go-to patent litigator and earning her a spot on Law360's list of 2015 Life Sciences MVPs.
A Pennsylvania federal judge on Monday issued a second order finding heart monitoring company MedTel24 Inc. in contempt of a consent judgment in a patent infringement case brought by CardioNet LLC, but he stopped short of issuing sanctions against it.
Pozen Inc. has urged the Patent Trial and Appeal Board to reject the latest attempt by an organization tied to hedge fund manager Kyle Bass to obtain an America Invents Act review of a patent covering the arthritis medication Vimovo, saying Bass' group didn’t show that it will succeed in invalidating the patent.
Proctor & Gamble recently urged the Eleventh Circuit not to revive multidistrict litigation claiming that zinc in Fixodent denture glue can cause neurological damage, saying a lower court didn’t err in concluding scientific evidence submitted by the denture users was too unreliable.
A California federal judge on Wednesday refused to disqualify 12 law firms representing retailers in pay-for-delay multidistrict litigation over the Lidoderm pain relief patch, saying plaintiffs’ attorneys’ use of a privileged document mistakenly handed over by Japanese drugmaker Teikoku did not warrant disqualification.
Bio-Rad Laboratories Inc. is planning to ask the Ninth Circuit to immediately review a California federal court’s recent refusal to toss claims in its former general counsel’s whistleblower suit alleging he was fired after reporting that company leadership potentially engaged in overseas bribery.
The Medicines Co. on Tuesday asked the Federal Circuit to reopen a case in which it reversed an infringement ruling against Mylan Inc. for a patent for the anticoagulant Angiomax, as the court has agreed to reconsider the patent’s validity in another suit.
An Atlanta jury hit Wright Medical Technology Inc. with an $11 million verdict Tuesday in the first bellwether trial in multidistrict litigation over its allegedly defective metal hip implant, finding that the plaintiff's implant was defective and that the company had misrepresented the safety of the device.
A California federal judge permanently dismissed a securities class action against supplement company Herbalife on Tuesday after finding that multiple opportunities to amend didn't get investors any closer to plausibility on their allegations that the company lied when it denied being a pyramid scheme.
China-based research and development service provider WuXi PharmaTech on Wednesday said that its shareholders have approved a $3.3 billion deal with a consortium of private equity investors and the company’s founders that will take the company private.
Kimberly-Clark urged a Wisconsin federal judge not to revive a rival’s claim that patent lawsuits instigated by the Pull-Ups maker demonstrate anti-competitive behavior, telling the judge Tuesday that First Quality is recycling old arguments.
The drug industry is anxiously awaiting new regulations from the U.S. Food and Drug Administration that could dramatically alter drug labeling in the U.S. and level the playing field for both generic and brand-name drug companies — but there is a sharp disagreement within the industry on what the FDA should do, say attorneys at Duane Morris LLP.
Several developments over the past few months caught the eye of Jim Maiwurm, chairman emeritus of Squire Patton Boggs. Try as he might, he could not resist the temptation to comment on a few — such as the expansion of the Dentons “polycentric” empire, a confused verein controversy, and provocative suggestions that the law firm partnership model is a dinosaur.
The Federal Circuit's majority opinion in ClearCorrect seems to provide a sweeping pronouncement regarding U.S. International Trade Commission jurisdiction, but the ITC likely will read the opinion narrowly to simply stand for the proposition that, where the only imported item is digital data that is transferred electronically from outside the U.S., the agency does not have jurisdiction, say Lyle Vander Schaaf and Yashas Honasoge o... (continued)
The amendments to the Federal Rules of Civil Procedure scheduled to take effect Dec. 1 are designed to usher in a new era in the U.S. litigation system, this time acknowledging that what was once known as “e-discovery” is now just discovery. The amendments are sweeping in scope, but none is more important than the revised Rule 37(e), say Gregory Leighton and Eric Choi of Neal Gerber & Eisenberg LLP.
Recognizing that defendants have no duty and little incentive to object to an inflated class counsel fee request, and that class counsel have every incentive to increase their fees, Judge Richard Posner and the Seventh Circuit have filled this void by directing “intense judicial scrutiny” of class counsel fee awards. In doing so, the court identified issues all counsel now should consider when crafting a class action settlement, sa... (continued)
A growing number of attorneys and firms are eschewing tradition by embracing technology to change not only the way we work, but also the way we organize our offices, says Anthony Johnson, founder and CEO of American Injury Attorney Group.
Over the past 35 years, Joe Kanka has experienced the corporate legal department from many angles, including management positions at a major law firm litigation support center, two legal staffing companies, and inside AT&T and Bell Atlantic. Here, he shares his 13 key business objectives that corporate legal departments must strive for in today’s business environment.
Laws prohibiting nonfunctional slack-fill in product packaging have existed for many years, mostly unnoticed. In recent years, however, district attorneys’ offices and the plaintiffs bar have increasingly initiated slack-fill litigation seeking recovery from a broad range of manufacturers, say attorneys at Sidley Austin LLP.
Now that the government has brought criminal charges under the Health Insurance Portability and Accountability Act against Warner Chilcott employees as well as a physician practice owner for alleged unlawful access to, and disclosure of, patient medical records, providers and vendors should re-examine their existing HIPAA policies, says Ellen Janos of Mintz Levin Cohn Ferris Glovsky and Popeo PC.
The Federal Circuit’s recent decision in Momenta v. Teva is significant because it not only narrows the scope of safe harbor protection for post-approval conduct but also seemingly eliminates such protection for research tools patents, say Brian Coggio and Ron Vogel of Fish & Richardson PC.